Prime-Boost Immunogenicity of Class 5C Protein from Neisseria meningitidis in Mice with Different Adjuvants

Abstract

The nasal route for vaccination offers both mucosal and systemic immunity for the prophylaxis of respiratory diseases. In order to induce maximal protective mucosal immunity, mucosal adjuvant is essential. Current studies are searching vaccinal antigens that are derived from the outer membrane protein (OMP) of Neisseria meningitidis. This study investigated the immunogenicity of intranasally administered class 5C protein of Neisseria meningitidis B employing purified LPS of the immunotypes (L3, 7, 9 or L8), cholera toxin and whole cells of Bordetella pertussis as mucosal adjuvants for the development of new meningococcal vaccine. In conclusion, the nasal delivery of class 5C with mucosal adjuvants has considerable potential in the development of a mucosal vaccine against serogroup B meningococci in a prime boost immunization in the presence of the adjuvants used. A monoclonal antibody against class 5 C protein using popliteal lymph nodes was obtained.

The Design of New Adjuvants for Mucosal Immunity toNeisseria meningitidisB in Nasally Primed Neonatal Mice for Adult Immune Response

“…To evaluate the effect of the vaccination strategy on the elicited IgG response, we analyzed the predominance of the IgG1, IgG2a, or IgG2b isotypes, Figure 5 —representative of Th2- and Th1-type immunity, respectively—within the pool of specific serum antibodies using OMP Stx1 or Stx2 toxoids or CT. As previously reported by our group, when the prime-boost schedule was used with other antigens, such as NOMV of N. lactamica in neonatal [ 27 ] or adult mice [ 33 ] with a purified protein of N. meningitidis , an immune response could be induced quickly.…”

“…In the case of the less abundant and less variable antigens, vaccines are likely to consist of multiple components to take advantage of synergistic effects. New meningococcal vaccine formulations may also include novel adjuvants to ensure potent bactericidal antibody responses [ 27 , 33 ].…”